Abu Dhabi completes UAE's first non-surgical liver tumour treatment, cuts stays from 10 days to 3

An Abu Dhabi hospital treated liver tumours without open surgery for the first time in the UAE on 10 April 2026, replacing invasive hepatic resection with an ablation-based procedure that cuts hospital stays from 7-10 days to 1-3 days.

The procedure means the Department of Health Abu Dhabi (DOH) has approved clinical pathways for advanced interventional oncology in the emirate. For hospital operators, it opens a new service line where regulatory approval has until now trailed clinical capability.

What the procedure means for operators

Non-surgical liver tumour treatments fall into two categories: thermal ablation (radiofrequency or microwave) and transarterial therapies (chemoembolisation or radioembolisation). Both require interventional radiology suites, specialised imaging equipment, and multidisciplinary tumour boards.

The cost difference is stark. Open liver surgery in the UAE carries an average billed cost of AED 120,000-180,000, while percutaneous ablation procedures typically bill at AED 40,000-70,000. For CFOs at private hospital groups, the margin profile differs: lower revenue per case but higher throughput, fewer ICU bed-days consumed, and reduced complication-related readmissions.

COOs should note that DOH facility licensing for interventional oncology requires specific equipment certifications and staffing ratios. Hospitals that want to replicate this capability will need at minimum a C-arm fluoroscopy unit, CT or ultrasound guidance systems, and at least two interventional radiologists credentialed through DOH's specialist registration process.

Abu Dhabi's oncology capacity in context

The UAE diagnosed an estimated 4,500 new cancer cases in 2024, according to the International Agency for Research on Cancer. Liver cancer ranks among the top 10 cancers in the country, driven partly by hepatitis B and C prevalence in the broader Middle East and South Asian expatriate populations.

The National Health Insurance Company (Daman) covers most oncology treatments under Abu Dhabi's mandatory health insurance scheme, and DOH's Jawda quality programme tracks cancer care outcomes across licensed facilities. Non-surgical liver treatments will add another metric to these quality benchmarks.

Liver ablation procedures are already standard of care at leading centres in South Korea, Japan, and parts of Europe. UAE patients who previously flew to Seoul or Barcelona for these treatments now have a domestic option, which fits the Abu Dhabi Healthcare Strategic Plan's targets for medical tourism and subspecialty capacity.

What to watch

Several questions remain for the sector:

• Whether DOH will issue specific clinical guidelines for non-surgical hepatic oncology, or defer to existing interventional radiology frameworks
• How quickly Dubai Health Authority (DHA) and Ministry of Health and Prevention (MOHAP) approve equivalent procedures in their jurisdictions
• Whether insurers will create distinct DRG codes for ablation-based liver treatments, which affects reimbursement speed
• The pipeline of trained interventional oncologists available in the UAE workforce

For medical directors evaluating whether to build this capability, the clinical evidence is established. A 2023 meta-analysis in The Lancet Gastroenterology found that thermal ablation matched surgical resection in 5-year survival rates for tumours under 3 cm, with significantly lower perioperative mortality.

Abu Dhabi's head start is likely short-lived. At least two Dubai-based hospital groups are expected to announce similar programmes within 6-12 months.